New cocktail aims to stop Chemo-Induced sickness in stem cell transplants

NCT ID NCT07413809

Recruiting now Symptom relief Sponsor: The Affiliated People's Hospital of Ningbo University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding olanzapine to two standard anti-nausea drugs works better than the usual treatment for preventing delayed nausea and vomiting after high-dose chemotherapy. The trial involves 92 multiple myeloma patients undergoing autologous stem cell transplant. Researchers will compare how many patients have no vomiting and need no rescue medication in the days after chemo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fosaprepitant, tropisetron, olanzapine, and dexamethasone
What this could lead to: If successful, this could offer a better way to prevent severe nausea and vomiting after high-dose chemotherapy, improving comfort during stem cell transplant.
What could go wrong: This is a relatively small trial (92 people) and only tests one specific chemo regimen. The new combo may not work better than the standard, and olanzapine can cause side effects like drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

The Affiliated People's Hospital of Ningbo University
RECRUITING

Ningbo, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.